Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Allegheny Singer Research Institute is engaged in the Biotechnology & Pharmaceuticals technology area with 3 pending office actions. These 3 actions are distributed among 3 distinct examiners, indicating that each matter is being handled by a separate individual. Despite having multiple examiners, all 3 pending actions are concentrated within 1 distinct art unit.
The busiest examiner for the portfolio is WRIGHT, KRYSTEN NIKOLE, who is currently managing 1 pending office action. This matches the distribution across the other distinct examiners, as each is responsible for exactly one of the 3 pending office actions. The concentration of all matters into 1 distinct art unit suggests a very specific technical focus within the biotechnology and pharmaceutical sectors.
With 3 pending office actions and 3 distinct examiners, the institute's prosecution is spread across different individuals but remains within a single examination group. The busiest examiner pending count of 1 confirms that no single examiner is handling multiple cases for the institute at this time. This structure allows for different perspectives from 3 distinct examiners while maintaining a consistent art unit environment.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WRIGHT, KRYSTEN NIKOLE | 1 | 0.0% | +0.0% |
| MATALKAH, FATIMAH KHALAF | 1 | 54.8% | +28.6% |
| MACFARLANE, STACEY NEE | 1 | 53.5% | +39.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19254170 | OPTIMIZING EMERGENCY MEDICAL ASSESSMENT AND TREATMENT WITH ARTIFICIAL INTELLIGENCE TOOLS | WRIGHT, KRYSTEN NIKOLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18700852 | INTERLEUKIN 7 AND INTERLEUKIN 21 FUSION PROTEINS | MATALKAH, FATIMAH KHALAF | — |
| 18246792 | Methods for Determining a Level of Cell-Bound Complement Activation Product | MACFARLANE, STACEY NEE | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19254170 | OPTIMIZING EMERGENCY MEDICAL ASSESSMENT AND TREATMENT WITH ARTIFICIAL INTELLIGENCE TOOLS | WRIGHT, KRYSTEN NIKOLE | — | §101§103 | Non-Final OA | — | Pending | Jun 30, 2025 |
| 18700852 | INTERLEUKIN 7 AND INTERLEUKIN 21 FUSION PROTEINS | MATALKAH, FATIMAH KHALAF | — | §103 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18246792 | Methods for Determining a Level of Cell-Bound Complement Activation Product | MACFARLANE, STACEY NEE | 1675 | §103§112DP | Non-Final OA | — | Pending | Mar 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial